COVAXIN | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Saturday
May 10, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SATURDAY, MAY 10, 2025

COVAXIN

Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket
Coronavirus chronicle

Indian drug regulator okays Covaxin for 6-12 year olds, Corbevax for 5-12 bracket

Covaxin is produced by Bharat Biotech and is one of the vaccines being used in the nationwide inoculation drive. Photo :AFP via Hindustan Times
Coronavirus chronicle

Bharat Biotech on WHO's Covaxin supply suspension: No impact on efficacy, safety

WHO suspends Covaxin supplies under UN procurement
Coronavirus chronicle

WHO suspends Covaxin supplies under UN procurement

A healthcare worker prepares to administer a dose of the Oxford University-AstraZeneca vaccine, marketed by the Serum Institute of India (SII) as COVISHIELD, against the coronavirus disease (COVID-19), in Santiago, Dominican Republic February 17, 2021. REUTERS/Ricardo Rojas/File Photo
Coronavirus chronicle

India gives conditional market nod for Covishield and Covaxin

A woman receives a booster dose of Covaxin, a coronavirus disease (Covid-19) vaccine manufactured by Bharat Biotech, at a vaccination centre in New Delhi, India, January 10, 2022. Photo :Reuters
Coronavirus chronicle

India's Bharat Biotech says Covaxin booster shot neutralises Omicron

Covaxin 77.8% effective against Covid-19 in Lancet study
Coronavirus chronicle

Covaxin 77.8% effective against Covid-19 in Lancet study

UK to add China's Sinovac, India's Covaxin to approved vaccine list
Coronavirus chronicle

UK to add China's Sinovac, India's Covaxin to approved vaccine list

A health worker displays a vial of the Covaxin vaccine at a health centre in New Delhi. Photo: AFP via Hindustan Times
Coronavirus chronicle

After WHO nod, travellers vaccinated with Covaxin allowed to enter US from Nov 8

WHO issues emergency use listing for COVAXIN Covid-19 jab
Coronavirus chronicle

WHO issues emergency use listing for COVAXIN Covid-19 jab

Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech's COVID-19 vaccine called COVAXIN, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi
Coronavirus chronicle

Review of India's Covaxin shot underway, WHO says

The study found that immunisation with a combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine was not only safe but also elicited better immunogenicity. Photo: UNB
Coronavirus chronicle

Better immune response from mixing Covaxin, Covishield, says ICMR study

Union health minister Mansukh Mandaviya said that India has administered 470 million doses of Covid-19 vaccine so far.(HT File Photo)
Coronavirus chronicle

Covishield output to be increased to 120 million, Covaxin to 58 million: Govt

Indian Covaxin to be permitted for trial in Bangladesh
Covid-19 in Bangladesh

Indian Covaxin to be permitted for trial in Bangladesh

  • Show More
  • loading...
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net